lirilumab
Drug timelines are a Plus or Pro feature.
8 regulatory and trial events tracked for lirilumab, covering 2015-07-22 to 2023-02-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors [Phase 1, Phase 2]